ヒュミラの市場規模、シェア、動向分析レポート：製品別、用途別、流通チャネル別、地域別、セグメント予測、2025～2030年

ヒュミラ市場の成長と動向

Grand View Research、Inc.の最新レポートによると、世界のヒュミラの市場規模は2030年までに41億1,000万米ドルとなり、予測期間中のCAGRは-11.29%で減少すると予測されています。

このような減少にもかかわらず、関節リウマチ、クローン病、潰瘍性大腸炎などの自己免疫疾患の世界の有病率の上昇に牽引され、市場は引き続き持続的な需要を経験しています。ヒュミラは長年にわたりこれらの疾患の治療の要となっており、有効な生物学的製剤に対する需要は依然として旺盛です。しかし、市場力学が変化する中、バイオシミラーの参入と規制の枠組みが進化しています。

ヒュミラの市場シェアが低下したのは、バイオシミラーの利用可能性が高まったことが主な原因です。主要な特許が失効し、規制当局の支援とコスト抑制戦略に後押しされたバイオシミラーは、特に新興市場においてますます入手しやすくなっています。その結果、より安価な代替品へのシフトが進み、バイオシミラーの採用が増加し、患者のアクセスが拡大しています。ヒュミラの有効性は証明されており、自己免疫疾患の治療薬として最重要の選択肢であり続けていますが、バイオシミラーの存在感が高まるにつれて価格競争環境が激化し、市場全体の優位性は低下しています。

市場が縮小しているとはいえ、特にヘルスケアインフラが整備され、自己免疫疾患に対する認識が高まっている新興国市場においては、大きな成長機会が残されています。ヒュミラの適応拡大や、クエン酸塩を含まない製剤や高濃度注射剤などの新しい製剤は、特にヘルスケアの枠組みや償還支援が充実している地域において、ヒュミラに対する継続的な需要を後押ししています。

AbbVieやAmgen、Sandoz、Tevaなどの主要バイオシミラーメーカーを含む製薬企業は、戦略的提携、製品の差別化、ライフサイクル管理を通じて、進化する情勢に対応しています。AbbVieは、2024年にバイオシミラーが登場するにもかかわらず、ブランドロイヤルティ、豊富な臨床データ、医師の信頼によって大きな市場シェアを維持しています。

Simlandiのような互換性のあるバイオシミラーの発売や、Evernorthの自己負担ゼロプログラムのような最近の動向は、手頃な価格でのアクセスを求める動きが強まっていることを浮き彫りにしています。バイオシミラーが急速に承認され、市場での存在感を増すにつれ、ヒュミラ業界の競合情勢はますますダイナミックになっています。ヒュミラ市場は今後も進化を続け、主要企業は適応症の拡大、デリバリーシステムの強化、未開拓地域への浸透に注力し、自己免疫疾患治療の力学の変化に対応していくものと予想されます。

ヒュミラ市場レポートハイライト

• 製品別では、先発品が市場を席巻し、2024年のシェアは87.0%に達しました。この優位性は、臨床的有効性が実証されていること、複数の自己免疫疾患において幅広い規制当局の承認が得られていること、医師や患者から同ブランドに対する長年の信頼が得られていることに起因しています。
• 用途別では、関節リウマチが市場を独占し、2024年には20.5％のシェアを占めました。
• 流通チャネル別では、病院薬局が市場をリードし、2024年には41.0%のシェアを占めました。ヒュミラは、専門的な治療を必要とする患者に対して、病院を通じて処方・調剤される治療オプションとして好まれています。
• 同市場の主要企業には、AbbVie、Amgen、Boehringer Ingelheim、Pfizer、Samsung Bioepis、Sandozなどがあります。特にヒュミラの主要特許が切れ、アダリムマブをベースとした幅広い治療法に市場が開放されたことで、バイオシミラーメーカーの存在感が高まり、競合は激化しています。
• 2024年6月、Coherus BioSciencesは、ヒュミラのバイオシミラーであるYUSIMRYのHong Kong King-Friend Industrial Co. Ltd.への売却を完了したことを明らかにしました。Hong Kong King-Friend Industrial Co. Ltd.に現金4,000万米ドルで売却し、この取引は2024年6月26日に完了しました。YUSIMRYは、HKFの子会社であるMeitheal Pharmaceuticalsにより米国で引き続き商業化されます。Coherusは、今回の事業売却は、がん領域のポートフォリオの強化という同社の戦略的焦点に沿ったものであると述べています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ヒュミラ市場の変数、動向、範囲

• 市場系統展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ビジネス環境分析
  • 業界分析- ポーターのファイブフォース分析
  • PESTLE分析
  • パイプライン分析
  • 特許満了分析
  • 価格分析

第4章 ヒュミラ市場：製品別、ビジネス分析

• 製品市場シェア、2024年および2030年
• 製品セグメントダッシュボード
• 市場規模、予測、動向分析（製品別、2018～2030年）
• 先発品
• バイオシミラー

第5章 ヒュミラ市場：用途別、ビジネス分析

• 用途市場シェア、2024年および2030年
• 用途セグメントダッシュボード
• 市場規模、予測、動向分析（用途別、2018～2030年）
• 関節リウマチ
• 乾癬性関節炎
• クローン病
• 潰瘍性大腸炎
• 強直性脊椎炎
• その他

第6章 ヒュミラ市場：流通チャネル別、ビジネス分析

• 流通チャネル市場シェア、2024年および2030年
• 流通チャネルセグメントダッシュボード
• 市場規模、予測、動向分析（流通チャネル別、2018～2030年）
• 病院薬局
• 小売薬局
• オンライン薬局

第7章 ヒュミラ市場：地域別、推定・動向分析

• 地域別市場シェア分析、2024年および2030年
• 地域市場ダッシュボード
• 市場規模と予測動向分析、2018～2030年
• 北米
  • 国別、2018～2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東およびアフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 参加者概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/上場企業
  • AbbVie
  • Alvotech
  • Amgen Inc.
  • Boehringer Ingelheim Pharmaceuticals Inc.
  • Celltrion Inc.
  • Coherus Biosciences、Inc
  • Fresenius Kabi AG
  • Fujiflim Kyowa Kiran Biologics Co.、Ltd.
  • Pfizer Inc.
  • Samsung Bioepis
  • Sandoz Inc.

List of Tables

• Table 1. List of secondary sources
• Table 2. List of abbreviations
• Table 3. Global Humira market, by region, 2018 - 2030 (USD Million)
• Table 4. Global Humira market, by product, 2018 - 2030 (USD Million)
• Table 5. Global Humira market, by application, 2018 - 2030 (USD Million)
• Table 6. Global Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 7. North America Humira market, by country, 2018 - 2030 (USD Million)
• Table 8. North America Humira market, by product, 2018 - 2030 (USD Million)
• Table 9. North America Humira market, by application, 2018 - 2030 (USD Million)
• Table 10. North America Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 11. U.S. Humira market, by product, 2018 - 2030 (USD Million)
• Table 12. U.S. Humira market, by application, 2018 - 2030 (USD Million)
• Table 13. U.S. Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 14. Canada Humira market, by product, 2018 - 2030 (USD Million)
• Table 15. Canada Humira market, by application, 2018 - 2030 (USD Million)
• Table 16. Canada Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 17. Mexico Humira market, by product, 2018 - 2030 (USD Million)
• Table 18. Mexico Humira market, by application, 2018 - 2030 (USD Million)
• Table 19. Mexico Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 20. Europe Humira market, by country, 2018 - 2030 (USD Million)
• Table 21. Europe Humira market, by product, 2018 - 2030 (USD Million)
• Table 22. Europe Humira market, by application, 2018 - 2030 (USD Million)
• Table 23. Europe Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 24. UK Humira market, by product, 2018 - 2030 (USD Million)
• Table 25. UK Humira market, by application, 2018 - 2030 (USD Million)
• Table 26. UK Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 27. Germany Humira market, by product, 2018 - 2030 (USD Million)
• Table 28. Germany Humira market, by application, 2018 - 2030 (USD Million)
• Table 29. Germany Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 30. France Humira market, by product, 2018 - 2030 (USD Million)
• Table 31. France Humira market, by application, 2018 - 2030 (USD Million)
• Table 32. France Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 33. Italy Humira market, by product, 2018 - 2030 (USD Million)
• Table 34. Italy Humira market, by application, 2018 - 2030 (USD Million)
• Table 35. Italy Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 36. Spain Humira market, by product, 2018 - 2030 (USD Million)
• Table 37. Spain Humira market, by application, 2018 - 2030 (USD Million)
• Table 38. Spain Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 39. Norway Humira market, by product, 2018 - 2030 (USD Million)
• Table 40. Norway Humira market, by application, 2018 - 2030 (USD Million)
• Table 41. Norway Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 42. Denmark Humira market, by product, 2018 - 2030 (USD Million)
• Table 43. Denmark Humira market, by application, 2018 - 2030 (USD Million)
• Table 44. Denmark Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 45. Sweden Humira market, by product, 2018 - 2030 (USD Million)
• Table 46. Sweden Humira market, by application, 2018 - 2030 (USD Million)
• Table 47. Sweden Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 48. Asia Pacific Humira market, by country, 2018 - 2030 (USD Million)
• Table 49. Asia Pacific Humira market, by product, 2018 - 2030 (USD Million)
• Table 50. Asia Pacific Humira market, by application, 2018 - 2030 (USD Million)
• Table 51. Asia Pacific Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 52. Japan Humira market, by product, 2018 - 2030 (USD Million)
• Table 53. Japan Humira market, by application, 2018 - 2030 (USD Million)
• Table 54. Japan Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 55. China Humira market, by product, 2018 - 2030 (USD Million)
• Table 56. China Humira market, by application, 2018 - 2030 (USD Million)
• Table 57. China Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 58. India Humira market, by product, 2018 - 2030 (USD Million)
• Table 59. India Humira market, by application, 2018 - 2030 (USD Million)
• Table 60. India Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 61. Australia Humira market, by product, 2018 - 2030 (USD Million)
• Table 62. Australia Humira market, by application, 2018 - 2030 (USD Million)
• Table 63. Australia Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 64. South Korea Humira market, by product, 2018 - 2030 (USD Million)
• Table 65. South Korea Humira market, by application, 2018 - 2030 (USD Million)
• Table 66. South Korea Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 67. Thailand Humira market, by product, 2018 - 2030 (USD Million)
• Table 68. Thailand Humira market, by application, 2018 - 2030 (USD Million)
• Table 69. Thailand Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 70. Latin America Humira market, by country, 2018 - 2030 (USD Million)
• Table 71. Latin America Humira market, by product, 2018 - 2030 (USD Million)
• Table 72. Latin America Humira market, by application, 2018 - 2030 (USD Million)
• Table 73. Latin America Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 74. Brazil Humira market, by product, 2018 - 2030 (USD Million)
• Table 75. Brazil Humira market, by application, 2018 - 2030 (USD Million)
• Table 76. Brazil Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 77. Argentina Humira market, by product, 2018 - 2030 (USD Million)
• Table 78. Argentina Humira market, by application, 2018 - 2030 (USD Million)
• Table 79. Argentina Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 80. Middle East & Africa Humira market, by country, 2018 - 2030 (USD Million)
• Table 81. Middle East & Africa Humira market, by product, 2018 - 2030 (USD Million)
• Table 82. Middle East & Africa Humira market, by application, 2018 - 2030 (USD Million)
• Table 83. Middle East & Africa Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 84. South Africa Humira market, by product, 2018 - 2030 (USD Million)
• Table 85. South Africa Humira market, by application, 2018 - 2030 (USD Million)
• Table 86. South Africa Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 87. Saudi Arabia Humira market, by product, 2018 - 2030 (USD Million)
• Table 88. Saudi Arabia Humira market, by application, 2018 - 2030 (USD Million)
• Table 89. Saudi Arabia Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 90. UAE Humira market, by product, 2018 - 2030 (USD Million)
• Table 91. UAE Humira market, by application, 2018 - 2030 (USD Million)
• Table 92. UAE Humira market, by distribution channel, 2018 - 2030 (USD Million)
• Table 93. Kuwait Humira market, by product, 2018 - 2030 (USD Million)
• Table 94. Kuwait Humira market, by application, 2018 - 2030 (USD Million)
• Table 95. Kuwait Humira market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Humira market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Therapeutic approach and application outlook (USD Million)
• Fig. 10 Competitive landscape
• Fig. 11 Humira market dynamics
• Fig. 12 Humira market: Porter's five forces analysis
• Fig. 13 Humira market: PESTLE analysis
• Fig. 14 Product market, 2018 - 2030 (USD Million)
• Fig. 15 Branded market, 2018 - 2030 (USD Million)
• Fig. 16 Biosimilar market, 2018 - 2030 (USD Million)
• Fig. 17 Application market, 2018 - 2030 (USD Million)
• Fig. 18 Rheumatoid Arthritis market, 2018 - 2030 (USD Million)
• Fig. 19 Psoriatic Arthritis market, 2018 - 2030 (USD Million)
• Fig. 20 Crohn's Diseases market, 2018 - 2030 (USD Million)
• Fig. 21 Ulcerative Colitis market, 2018 - 2030 (USD Million)
• Fig. 22 Ankylosing Spondylitis market, 2018 - 2030 (USD Million)
• Fig. 23 Others market, 2018 - 2030 (USD Million)
• Fig. 24 Distribution Channel market, 2018 - 2030 (USD Million)
• Fig. 25 Hospital Pharmacies market, 2018 - 2030 (USD Million)
• Fig. 26 Retail Pharmacies market, 2018 - 2030 (USD Million)
• Fig. 27 Online Pharmacies market, 2018 - 2030 (USD Million)
• Fig. 28 Humira market revenue, by region
• Fig. 29 Regional marketplace: Key takeaways
• Fig. 30 Regional marketplace: Key takeaways
• Fig. 31 North America Humira market, 2018 - 2030 (USD Million)
• Fig. 32 U.S. country dynamics
• Fig. 33 U.S. Humira market, 2018 - 2030 (USD Million)
• Fig. 34 Canada country dynamics
• Fig. 35 Canada Humira market, 2018 - 2030 (USD Million)
• Fig. 36 Mexico country dynamics
• Fig. 37 Mexico Humira market, 2018 - 2030 (USD Million)
• Fig. 38 Europe Humira market, 2018 - 2030 (USD Million)
• Fig. 39 UK country dynamics
• Fig. 40 UK Humira market, 2018 - 2030 (USD Million)
• Fig. 41 Germany country dynamics
• Fig. 42 Germany Humira market, 2018 - 2030 (USD Million)
• Fig. 43 France country dynamics
• Fig. 44 France Humira market, 2018 - 2030 (USD Million)
• Fig. 45 Italy country dynamics
• Fig. 46 Italy Humira market, 2018 - 2030 (USD Million)
• Fig. 47 Spain country dynamics
• Fig. 48 Spain Humira market, 2018 - 2030 (USD Million)
• Fig. 49 Norway country dynamics
• Fig. 50 Norway Humira market, 2018 - 2030 (USD Million)
• Fig. 51 Sweden country dynamics
• Fig. 52 Sweden Humira market, 2018 - 2030 (USD Million)
• Fig. 53 Denmark country dynamics
• Fig. 54 Denmark Humira market, 2018 - 2030 (USD Million)
• Fig. 55 Asia Pacific Humira market, 2018 - 2030 (USD Million)
• Fig. 56 Japan country dynamics
• Fig. 57 Japan Humira market, 2018 - 2030 (USD Million)
• Fig. 58 China country dynamics
• Fig. 59 China Humira market, 2018 - 2030 (USD Million)
• Fig. 60 India country dynamics
• Fig. 61 India Humira market, 2018 - 2030 (USD Million)
• Fig. 62 Australia country dynamics
• Fig. 63 Australia Humira market, 2018 - 2030 (USD Million)
• Fig. 64 South Korea country dynamics
• Fig. 65 South Korea Humira market, 2018 - 2030 (USD Million)
• Fig. 66 Thailand country dynamics
• Fig. 67 Thailand Humira market, 2018 - 2030 (USD Million)
• Fig. 68 Latin America Humira market, 2018 - 2030 (USD Million)
• Fig. 69 Brazil country dynamics
• Fig. 70 Brazil Humira market, 2018 - 2030 (USD Million)
• Fig. 71 Argentina country dynamics
• Fig. 72 Argentina Humira market, 2018 - 2030 (USD Million)
• Fig. 73 MEA Humira market, 2018 - 2030 (USD Million)
• Fig. 74 South Africa country dynamics
• Fig. 75 South Africa Humira market, 2018 - 2030 (USD Million)
• Fig. 76 Saudi Arabia country dynamics
• Fig. 77 Saudi Arabia Humira market, 2018 - 2030 (USD Million)
• Fig. 78 UAE country dynamics
• Fig. 79 UAE Humira market, 2018 - 2030 (USD Million)
• Fig. 80 Kuwait country dynamics
• Fig. 81 Kuwait Humira market, 2018 - 2030 (USD Million)
• Fig. 82 Company categorization
• Fig. 83 Company market position analysis
• Fig. 84 Strategic framework

Humira Market Growth & Trends:

The global humira market size is projected to reach USD 4.11 billion by 2030, declining at a CAGR of -11.29% during the forecast period, according to a new report by Grand View Research, Inc. Despite this decline, the market continues to experience sustained demand, driven by the rising global prevalence of autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. Humira has long been a cornerstone of treatment for these conditions, and demand for effective biologic therapies remains strong. However, as the market shifts, the entry of biosimilars and evolving regulatory frameworks are reshaping its dynamics.

The decline in Humira's market share is largely attributed to the growing availability of biosimilars. With the expiration of key patents, biosimilars, driven by regulatory support and cost-containment strategies, are becoming increasingly accessible, particularly in emerging markets. As a result, there is a shift towards more affordable alternatives, increasing the adoption of biosimilars and expanding patient access. Although Humira's proven efficacy continues to make it a top choice for managing autoimmune diseases, the increasing presence of biosimilars leads to a competitive pricing environment and reduces its overall market dominance.

Despite the market's decline, significant growth opportunities remain, especially in developing regions where healthcare infrastructure is improving and awareness of autoimmune conditions is rising. The expanding indications for Humira and new formulations, such as citrate-free versions and high-concentration injectables, drive continued demand for the drug, particularly in regions with a strong healthcare framework and reimbursement support.

Pharmaceutical companies, including AbbVie and leading biosimilar manufacturers like Amgen, Sandoz, and Teva, are navigating the evolving landscape through strategic partnerships, product differentiation, and lifecycle management. AbbVie has retained significant market share through brand loyalty, extensive clinical data, and physician trust, despite the emergence of biosimilars in 2024.

Recent developments, such as the launch of interchangeable biosimilars like Simlandi and initiatives like Evernorth's zero out-of-pocket cost program, highlight the growing push for affordable access. As biosimilars rapidly gain approval and expand market presence, the competitive landscape of the Humira industry is becoming increasingly dynamic. The market is expected to continue evolving, with key players focusing on expanding indications, enhancing delivery systems, and penetrating underserved regions to capitalize on the shifting dynamics of autoimmune disease treatment.

Humira Market Report Highlights:

• Based on product, Branded Humira dominated the market, accounting for 87.0% of the share in 2024. This dominance is attributed to its proven clinical efficacy, wide-ranging regulatory approvals across multiple autoimmune conditions, and long-standing physician and patient trust in the brand.
• Based on application, rheumatoid arthritis dominated the market and accounted for a share of 20.5% in 2024, driven by its rising global prevalence and increasing adoption of advanced therapies.
• Based on distribution channel, hospital Pharmacies led the market and accounted for a share of 41.0% in 2024, driven by the growing demand for biologic therapies used in managing autoimmune conditions. Humira is a preferred treatment option prescribed and dispensed through hospital settings for patients requiring specialized care.
• Key players in the market include AbbVie, Amgen, Boehringer Ingelheim, Pfizer, Samsung Bioepis, and Sandoz. Competition is intensifying with the growing presence of biosimilar manufacturers, especially following the expiration of Humira's key patents, which has opened the market to a broader range of adalimumab-based therapies.
• In June 2024, Coherus BioSciences revealed it had completed the sale of its Humira biosimilar, YUSIMRY, to Hong Kong King-Friend Industrial Co. Ltd. for USD 40 million in cash, with the transaction closing on June 26, 2024. YUSIMRY will continue to be commercialized in the U.S. by Meitheal Pharmaceuticals, a subsidiary of HKF. Coherus noted that the divestiture aligns with its strategic focus on advancing its oncology portfolio.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Humira Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Humira Market: Product Business Analysis

• 4.1. Product Market Share, 2024 & 2030
• 4.2. Product Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Branded
  • 4.4.1. Branded Market, 2018 - 2030 (USD Million)
• 4.5. Biosimilar
  • 4.5.1. Biosimilar Market, 2018 - 2030 (USD Million)

Chapter 5. Humira Market: Application Business Analysis

• 5.1. Application Market Share, 2024 & 2030
• 5.2. Application Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Rheumatoid Arthritis
  • 5.4.1. Rheumatoid Arthritis Market, 2018 - 2030 (USD Million)
• 5.5. Psoriatic Arthritis
  • 5.5.1. Psoriatic Arthritis Market, 2018 - 2030 (USD Million)
• 5.6. Crohn's Disease
  • 5.6.1. Crohn's Disease Market, 2018 - 2030 (USD Million)
• 5.7. Ulcerative Colitis
  • 5.7.1. Ulcerative Colitis Market, 2018 - 2030 (USD Million)
• 5.8. Ankylosing Spondylitis
  • 5.8.1. Ankylosing Spondylitis Market, 2018 - 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Humira Market: Distribution Channel Business Analysis

• 6.1. Distribution Channel Market Share, 2024 & 2030
• 6.2. Distribution Channel Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 6.4. Hospital Pharmacies
  • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
• 6.5. Retail Pharmacies
  • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
• 6.6. Online Pharmacies
  • 6.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Humira Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America Humira Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Target Disease Prevalence
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Framework
    • 7.4.2.5. U.S. Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Framework
    • 7.4.3.5. U.S. Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Framework
    • 7.4.4.5. Mexico Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Target Disease Prevalence
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Framework
    • 7.5.2.5. Uk Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Framework
    • 7.5.3.5. Germany Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Target Disease Prevalence
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement Framework
    • 7.5.4.5. France Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Target Disease Prevalence
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Reimbursement Framework
    • 7.5.5.5. Italy Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Target Disease Prevalence
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Reimbursement Framework
    • 7.5.6.5. Spain Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Target Disease Prevalence
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement Framework
    • 7.5.7.5. Denmark Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Target Disease Prevalence
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement Framework
    • 7.5.8.5. Sweden Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Target Disease Prevalence
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Reimbursement Framework
    • 7.5.9.5. Norway Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Target Disease Prevalence
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Framework
    • 7.6.2.5. Japan Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Framework
    • 7.6.3.5. China Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Target Disease Prevalence
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Framework
    • 7.6.4.5. India Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Target Disease Prevalence
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Framework
    • 7.6.5.5. Australia Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Target Disease Prevalence
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement Framework
    • 7.6.6.5. South Korea Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Target Disease Prevalence
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement Framework
    • 7.6.7.5. Thailand Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Target Disease Prevalence
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement Framework
    • 7.7.2.5. Japan Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Target Disease Prevalence
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement Framework
    • 7.7.3.5. China Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Middle East and Africa
  • 7.8.1. Middle East and Africa Humira Market Estimates and Forecasts, 2017 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Target Disease Prevalence
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement Framework
    • 7.8.2.5. South Africa Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Target Disease Prevalence
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement Framework
    • 7.8.3.5. Saudi Arabia Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Target Disease Prevalence
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Reimbursement Framework
    • 7.8.4.5. UAE Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Target Disease Prevalence
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Reimbursement Framework
    • 7.8.5.5. Kuwait Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. AbbVie
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Alvotech
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Amgen Inc.
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Boehringer Ingelheim Pharmaceuticals Inc.
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Celltrion Inc.
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Coherus Biosciences, Inc
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Fresenius Kabi AG
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Fujiflim Kyowa Kiran Biologics Co., Ltd.
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Pfizer Inc.
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Samsung Bioepis
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives
  • 8.5.11. Sandoz Inc.
    • 8.5.11.1. Overview
    • 8.5.11.2. Financial Performance
    • 8.5.11.3. Product Benchmarking
    • 8.5.11.4. Strategic Initiatives